Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.49
-0.0328-0.09%
Post-market: 36.490.00000.00%16:10 EDT
Volume:129
Turnover:5K
Market Cap:19.16M
PE:- -
High:36.49
Open:36.49
Low:36.49
Close:36.52
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.18
T/O Rate:0.02%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
4 hours ago

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
6 hours ago

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
6 hours ago

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
6 hours ago

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
6 hours ago

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
6 hours ago

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
8 hours ago

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

GlobeNewswire
·
Yesterday

Correction: Top Midday Decliners

MT Newswires Live
·
Yesterday

Press Release: Celcuity Appoints David Gryska to Its Board of Directors

Dow Jones
·
Yesterday

Verastem announces data from analysis of Phase 2 RAMP 201 trial

TIPRANKS
·
Yesterday

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Yesterday

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Yesterday

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Yesterday

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Yesterday

J&J - 60% Scalp Psoriasis, 89% Genital Psoriasis Patients Achieve Complete Clearance at Week 112

THOMSON REUTERS
·
Yesterday

J&J - Safety Findings Through Week 112 Consistent with Icotyde Profile, no New Safety Signals

THOMSON REUTERS
·
Yesterday

Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

TIPRANKS
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Yesterday